Author response: MicroRNA-26b protects against MASH development and can be efficiently targeted with lipid nanoparticles

Linsey J. F. Peters(Cardiovascular Institute Hospital), Emiel P. C. van der Vorst(RWTH Aachen University), Marcin Krawczyk(Universitätsklinikum des Saarlandes), Marion J. Gijbels(Maastricht University Medical Centre), Alexander Jans(Institute of Rheumatology), Peter Olinga(University of Groningen), Kiril Bidzhekov(Ludwig-Maximilians-Universität München), Cheng Lin(Institute of Rheumatology), Matthias Bartneck(DWI – Leibniz Institute for Interactive Materials), Andrea Bonnin-Marquez(RWTH Aachen University), Yvonne Döring(University of Bern), Sander S. Rensen(Maastricht University Medical Centre), Sanne L. Maas(German Centre for Cardiovascular Research), Yana Geng(Center for Digestive and Liver Diseases), Joachim Jankowski(Charité - Universitätsmedizin Berlin), Ronit Shiri‐Sverdlov(Maastricht University), Tom Houben(Maastricht University), Tim Hendrikx(Medical University of Vienna), Leonida Rakateli(RWTH Aachen University), Rosanna Huchzermeier(RWTH Aachen University), Malvina Brisbois(University Medical Center), Christian Weber(Munich Cluster for Systems Neurology), Alan Gorter(University of Groningen), Erik A.L. Biessen(Maastricht University Medical Centre)
Unknown
August 5, 2024
Cited by 0


Related Papers